TMCI TREACE MED CONCEPTS INC

Treace Medical Announces Settlement of Lawsuit Again Fusion Orthopedics

Treace Medical Announces Settlement of Lawsuit Again Fusion Orthopedics

PONTE VEDRA, Fla., March 03, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) jointly announces with Fusion Orthopedics, LLC (“Fusion Orthopedics”) that they have reached an amicable resolution of the litigation between the parties. Treace Medical filed the lawsuit on March 29, 2022 against Fusion Orthopedics in the United States District Court for the District of Arizona, alleging patent, trademark, and copyright infringement, as well as various unfair trade practices based on Fusion Orthopedics’ use, sale, and promotion of the Lapilock 4D Advanced Bunion Surgery, including false advertising and unfair competition. Fusion Orthopedics subsequently filed counterclaims against Treace Medical, requesting declaratory judgment of non-infringement and invalidity of the patents, declaratory judgment of invalidity of Treace Medical’s LAPIPLASTY trademark, as well as various unfair trade practices based on Treace Medical’s use, sale, and promotion of the Lapiplasty 3D Bunion Correction, including counterclaims of false descriptions and false advertising. In March 2023, the parties entered into an agreement to settle this matter.

While the terms of the settlement are confidential, Treace Medical is pleased with the outcome.

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace Medical has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace Medical recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit .

Contacts:

Treace Medical Concepts

Mark L. Hair

Chief Financial Officer



(904) 373-5940

Investors:

Gilmartin Group

Lynn Lewis or Vivian Cervantes



EN
03/03/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TREACE MED CONCEPTS INC

 PRESS RELEASE

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Fina...

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results PONTE VEDRA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the fourth quarter and full-year ended December 31, 2025. Recent Highlights Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025, an increase of 2% compared t...

 PRESS RELEASE

Treace Highlights New Product Innovations and Updated Positive Clinica...

Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will highlight new product innovations and present new interim data for the ALIGN3D™, MTA3D™, and SpeedMTP® clinical studies at the American College of Foot and Ankle Surgeons (“ACFAS”) Annu...

 PRESS RELEASE

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Res...

Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026 PONTE VEDRA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the fourth quarter and full year of 2025 before the open of trading on Friday, February 27, 2026. Company management will host a conference call to discuss financial results be...

 PRESS RELEASE

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2...

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period ...

 PRESS RELEASE

Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ ...

Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace’s market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, pr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch